BioCentury
ARTICLE | Company News

FDA grants new designation to Humacyte regenerative therapy

March 20, 2017 10:43 PM UTC

Humacyte Inc. (Research Triangle Park, N.C.) said FDA granted regenerative medicine advanced therapy designation to Humacyl for vascular access in hemodialysis patients. Created via the 21st Century Cures Act, the designation provides Humacyl with the same expedited development and regulatory review actions afforded drug candidates which receive FDA's breakthrough therapy designation (see BioCentury Extra, Jan. 24)...

BCIQ Company Profiles

Humacyte Inc.